Mary K. Moreland - Feb 21, 2024 Form 4 Insider Report for ABBOTT LABORATORIES (ABT)

Role
EXECUTIVE VICE PRESIDENT
Signature
/s/ Mary K. Moreland by Jessica H. Paik, Attorney-in-Fact
Stock symbol
ABT
Transactions as of
Feb 21, 2024
Transactions value $
$0
Form type
4
Date filed
2/23/2024, 05:38 PM
Previous filing
Mar 2, 2023
Next filing
Mar 4, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ABT Common shares without par value Award $0 +10.6K +12.12% $0.00 97.8K Feb 21, 2024 Direct F1
holding ABT Common shares without par value 11.4K Feb 21, 2024 Profit Sharing Trust F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ABT Option (right to buy) Award $0 +39.7K $0.00 39.7K Feb 21, 2024 Common Shares 39.7K $116.98 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes.
F2 Balance in the Abbott Laboratories Stock Retirement Trust as of February 21, 2024.
F3 Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 13,244 on February 21, 2025, 13,245 on February 21, 2026, and 13,245 on February 21, 2027.